Capricor Therapeutics (CAPR) Enterprise Value (2010 - 2026)

Capricor Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$278.6 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 92.44% year-over-year to -$278.6 million; the TTM figure through Mar 2026 stood at -$278.6 million (down 92.44% YoY), while the FY2025 annual figure was -$318.1 million, down 109.96% from the prior year.
• Enterprise Value for Q1 2026 stood at -$278.6 million, up from -$318.1 million in the prior quarter.
• The five-year high for Enterprise Value was -$28.5 million in Q3 2023, with the low at -$318.1 million in Q4 2025.
• The 5-year median for Enterprise Value is -$51.4 million (2022), against an average of -$95.1 million.
• The sharpest annual moves came in 2023 and 2025: Enterprise Value surged 38.81% in 2023, then sank 316.81% in 2025.
• Capricor Therapeutics' Enterprise Value stood at -$41.4 million in 2022, then climbed by 4.67% to -$39.5 million in 2023, then sank by 283.7% to -$151.5 million in 2024, then tumbled by 109.96% to -$318.1 million in 2025, then advanced by 12.42% to -$278.6 million in 2026.
• Business Quant data shows CAPR's Enterprise Value at -$278.6 million in Q1 2026, -$318.1 million in Q4 2025, and -$98.6 million in Q3 2025.